[go: up one dir, main page]

MX2012006401A - Proceso para preparar composiciones oftalmicas farmaceuticas. - Google Patents

Proceso para preparar composiciones oftalmicas farmaceuticas.

Info

Publication number
MX2012006401A
MX2012006401A MX2012006401A MX2012006401A MX2012006401A MX 2012006401 A MX2012006401 A MX 2012006401A MX 2012006401 A MX2012006401 A MX 2012006401A MX 2012006401 A MX2012006401 A MX 2012006401A MX 2012006401 A MX2012006401 A MX 2012006401A
Authority
MX
Mexico
Prior art keywords
preparing
slurry
compositions
carbonic anhydrase
anhydrase inhibitor
Prior art date
Application number
MX2012006401A
Other languages
English (en)
Inventor
Ashish Ashokrao Deshmukh
Shirishkumar Kulkarni
Pravin Meghrajji Bhutada
Sajeev Chandran
Original Assignee
Lupin Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lupin Ltd filed Critical Lupin Ltd
Publication of MX2012006401A publication Critical patent/MX2012006401A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Ophthalmology & Optometry (AREA)
  • Inorganic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Composiciones oftálmicas farmacéuticas que comprenden ingrediente(s) activos como inhibidor de anhidrasa carbónica (CAl) o combinaciones y procesos para realizar dichas composiciones y el uso de estas composiciones en poblaciones de pacientes que incluyen poblaciones pediátricas. Un proceso para preparar una composición oftálmica que comprende un inhibidor de anhidrasa carbónica que comprende a) preparar una suspensión que comprende un inhibidor de anhidrasa carbónica y un surfactante; b) preparar una suspensión de polímero que comprende un polímero y agua; c) preparar una solución que comprende la tonicidad y agentes conservadores; d) mezclar la suspensión del polímero del paso b y la solución del paso c, para formar un concentrado del excipiente líquido y ajustar un pH; e) agregar la suspensión del paso a, al concentrado del excipiente líquido del paso d y mezclar para homogenizar; f) realizar mediante autoclave la mezcla del paso e; g) medir la mezcla del paso f, bajo condición aséptica.
MX2012006401A 2009-12-03 2010-12-02 Proceso para preparar composiciones oftalmicas farmaceuticas. MX2012006401A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN1415KO2009 2009-12-03
PCT/IN2010/000784 WO2011067791A2 (en) 2009-12-03 2010-12-02 Process for preparing pharmaceutical ophthalmic compositions

Publications (1)

Publication Number Publication Date
MX2012006401A true MX2012006401A (es) 2012-07-10

Family

ID=44115377

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2012006401A MX2012006401A (es) 2009-12-03 2010-12-02 Proceso para preparar composiciones oftalmicas farmaceuticas.

Country Status (6)

Country Link
US (1) US8614210B2 (es)
EP (1) EP2506878A2 (es)
JP (1) JP5558582B2 (es)
AU (1) AU2010325632B2 (es)
MX (1) MX2012006401A (es)
WO (1) WO2011067791A2 (es)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20150119386A1 (en) 2012-05-21 2015-04-30 Aurobindo Pharma Limited Process for preparing opthalmic suspension of brinzolamide
WO2014057499A1 (en) 2012-10-11 2014-04-17 Indoco Remedies Limited A process for manufacturing sterile brinzolamide ophthalmic suspension
US20140377210A1 (en) * 2013-06-21 2014-12-25 Gnt, Llc Artificial tear compositions
WO2015056149A1 (en) * 2013-10-17 2015-04-23 Sentiss Pharma Private Limited Preservative-free ophthalmic pharmaceutical formulation
US10463674B2 (en) 2013-11-08 2019-11-05 Sentiss Pharma Private Limited Process for manufacturing sterile ophthalmic pharmaceutical suspensions
ES2838756T3 (es) * 2014-01-24 2021-07-02 Sentiss Pharma Private Ltd Composición farmacéutica que comprende brinzolamida
PL407710A1 (pl) * 2014-03-28 2015-10-12 Instytut Farmaceutyczny Sposób wytwarzania preparatu kropli do oczu w postaci zawiesiny zawierającej brynzolamid i preparat wytworzony tym sposobem
JP6279395B2 (ja) * 2014-05-01 2018-02-14 東亜薬品株式会社 ブリンゾラミド懸濁性点眼液組成物の製造方法
JP6373995B2 (ja) 2014-07-11 2018-08-15 富士フイルム株式会社 眼科用水性組成物
ES2954412T3 (es) * 2014-10-20 2023-11-22 Sentiss Pharma Private Ltd Solución oftálmica
ES2861806T3 (es) 2014-12-02 2021-10-06 Novartis Ag Fabricación de composiciones que contienen tensioactivo
US20170189352A1 (en) 2015-03-13 2017-07-06 Par Pharmaceutical, Inc. Epinephrine formulations
US9119876B1 (en) 2015-03-13 2015-09-01 Par Pharmaceutical, Inc. Epinephrine formulations
WO2020072979A1 (en) * 2018-10-04 2020-04-09 Miraki Innovation Think Tank Llc Slurry and solution compositions
KR102271247B1 (ko) * 2020-11-04 2021-06-30 삼천당제약주식회사 안과용 현탁액 조성물의 제조방법
CA3206106A1 (en) 2021-02-10 2022-08-18 Bhaskar Chaudhuri Methods for ophthalmic delivery of roflumilast
CN116867480A (zh) * 2021-02-10 2023-10-10 洛利克斯治疗有限公司 眼部递送罗氟司特的方法
AU2022353032A1 (en) 2021-09-22 2024-03-28 Iolyx Therapeutics, Inc. Methods of treating ocular inflammatory diseases

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5378703A (en) 1990-04-09 1995-01-03 Alcon Laboratories, Inc. Sulfonamides useful as carbonic anhydrase inhibitors
US6071904A (en) * 1996-12-11 2000-06-06 Alcon Laboratories, Inc. Process for manufacturing ophthalmic suspensions
US6258350B1 (en) * 1999-01-20 2001-07-10 Alcon Manufacturing, Ltd. Sustained release ophthalmic formulation
JP4766653B2 (ja) * 2005-01-28 2011-09-07 株式会社林原生物化学研究所 眼科用医薬組成物
WO2006108637A2 (de) * 2005-04-13 2006-10-19 Abbott Gmbh & Co.Kg Verfahren zur schonenden herstellung hochfeiner partikelsuspensionen und hochfeiner partikel sowie deren verwendung
US20070077303A1 (en) * 2005-09-30 2007-04-05 Azaam Alli Methods for providing oxidatively stable ophthalmic compositions

Also Published As

Publication number Publication date
JP5558582B2 (ja) 2014-07-23
AU2010325632A1 (en) 2012-06-21
AU2010325632B2 (en) 2014-01-30
WO2011067791A3 (en) 2011-09-09
US20120283252A1 (en) 2012-11-08
US8614210B2 (en) 2013-12-24
JP2013512894A (ja) 2013-04-18
EP2506878A2 (en) 2012-10-10
WO2011067791A2 (en) 2011-06-09

Similar Documents

Publication Publication Date Title
MX2012006401A (es) Proceso para preparar composiciones oftalmicas farmaceuticas.
MX2009009592A (es) Aminopiridinas utiles como inhibidores de proteinas cinasas.
MX2013006040A (es) Antagonistas del receptor de acido lisofosfatidico y su uso en el tratamiento de fibrosis.
TN2012000126A1 (en) Polycyclic compounds as lysophosphatidic acid receptor antagonists
EA200971116A1 (ru) Способ желатинизации фиброина шелка с применением обработки ультразвуком
EP4371615A3 (en) Treatment of amd using aav sflt-1
WO2007110422A3 (en) Whey protein vehicle for active agent delivery
WO2011041694A3 (en) Compounds as lysophosphatidic acid receptor antagonists
WO2011017350A3 (en) Compounds as lysophosphatidic acid receptor antagonists
WO2007077561A3 (en) Compositions and methods for enhancing in-vivo uptake of pharmaceutical agents
MX2011012839A (es) Antagonistas policiclicos de receptores de acido lisofosfatidico.
MX2015003653A (es) Derivados de amida del acido benzoimidazol-carboxilico como moduladores del receptor apj.
MY168079A (en) A novel formulation of diclofenac
MX348823B (es) Formulaciones estables de linaclotida.
DE602005021770D1 (de) Indol-1-yl-essigsäurederivate
PH12016500746A1 (en) A novel formulation of meloxicam
WO2011069037A3 (en) Stabilization and storage of biological pharmaceutical compositions
WO2007102127A3 (en) New amines
TW200738714A (en) New secondary amines
BR112014000080A2 (pt) dispositivo de reconstituição
WO2010101301A9 (en) Prophylaxis and treatment of macular degeneration and retinopathy using a prdx protein
CY1109541T1 (el) Φαρμακευτικη συνταγοποιηση για την θεραπεια οστεοαρθριτιδας η οποια περιεχει κλοδρονικο οξυ και υαλουρονικο οξυ
TW200711719A (en) Use of 2,3-dihydroxynaphthalene-6-sulfonic acid salts as dispersants
AR074724A1 (es) Sal de citrato 11-(2-pirrolidin-1-il-etoxi)-14,19-dioxa-5,7,26-triaza-tetraciclo (19.3.1.1(2,6).1(8,12) heptacosa-1-(25),2(26),3,5,8,10,12 (27),16,21,23-decaeno
HRP20120651T1 (hr) Postupak konzerviranja pića

Legal Events

Date Code Title Description
FA Abandonment or withdrawal